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Despite huge improvements in the treatment of leukemia, the percentage of patients 
suffering relapse still remains significant. Relapse most often results from a small number 
of leukemic stem cells (LSCs) within the bone marrow, which are able to self-renew, and 
therefore reestablish the full tumor. The marrow microenvironment contributes consider-
ably in supporting the protection and development of leukemic cells. LSCs share specific 
niches with normal hematopoietic stem cells with the niche itself being composed of 
a variety of cell types, including mesenchymal stem/stromal cells, bone cells, immune 
cells, neuronal cells, and vascular cells. A hallmark of the hematopoietic niche is low 
oxygen partial pressure, indeed this hypoxia is necessary for the long-term maintenance 
of hematopoietic stem/progenitor cells. Hypoxia is a strong signal, principally maintained 
by members of the hypoxia-inducible factor (HIF) family. In solid tumors, it has been well 
established that hypoxia triggers intrinsic metabolic changes and microenvironmental 
modifications, such as the stimulation of angiogenesis, through activation of HIFs. As leu-
kemia is not considered a “solid” tumor, the role of oxygen in the disease was presumed 
to be inconsequential and remained long overlooked. This view has now been revised 
since hypoxia has been shown to influence leukemic cell proliferation, differentiation, and 
resistance to chemotherapy. However, the role of HIF proteins remains controversial with 
HIFs being considered as either oncogenes or tumor suppressor genes, depending on 
the study and model. The purpose of this review is to highlight our knowledge of hypoxia 
and HIFs in leukemic development and therapeutic resistance and to discuss the recent 
hypoxia-based strategies proposed to eradicate leukemias.
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LeUKeMiAS AnD HYPOXiA
Leukemia is characterized by uncontrolled proliferation of hematopoietic cells within bone mar-
row (BM). Lymphoid leukemias can be distinguished from myeloid according to the abnormal cell 
lineage, and acute from chronic leukemias according to the maturity of the blood cells involved and 
progression rate. Acute leukemias are characterized by rapid proliferation of immature hematopoi-
etic cells, termed blasts, which fail to differentiate into mature cells. Their accumulation in BM also 
prevents growth and differentiation of normal hematopoietic cells. The clinical evolution is fast (1). 
In contrast, in chronic leukemia, the growth advantage of neoplastic cells leads to the generation 
of a more mature cell population that outcompetes normal hematopoiesis, and clinical evolution 
is longer (several months to years) (2). To date, although the majority of pediatric acute lymphoid 
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leukemia (ALL) and chronic myeloid leukemia (CML) cases (3) 
are cured or well controlled under treatment, chronic lymphoid 
leukemia (CLL) and, even more, acute myeloid leukemia (AML) 
have a high risk of relapse, despite therapeutic progressions (4). 
While treatments often target cycling cells, the idea that a small 
population of quiescent leukemic cells survive and trigger relapse 
regardless of treatment has emerged (5). In the early 90s, the team 
of John E. Dick established a hierarchy in leukemic cell populations 
which, by analogy with that of normal hematopoietic cells, led to 
the introduction of the concept of cancer stem cells for all cancers 
[reviewied in Ref. (5, 6)]. Their work identified a subpopulation of 
leukemic cells able to initiate leukemic growth after transplanta-
tion into immune-deficient mice. These stem-like cells, named 
leukemia-initiating cells (LICs) or leukemic stem cells (LSCs) 
(7, 8), arise from hematopoietic stem/progenitor cells (HSCs) 
that reside in the most hypoxic tissue areas within the normal 
HSC niche (9, 10). The oxygen partial pressure (ppO2) in tissues 
is much lower compared to that in the atmosphere (160 mmHg 
corresponding to around 21% oxygen). In particular, in BM an 
oxygen gradient exists ranging from <6% oxygen, close to the 
vessels, to anoxia in the most distant regions from blood vessels 
(11–15). However, O2 level differs according to the nature of the 
hematopoietic niche; the sinusoidal niche is around 10 mmHg 
(equivalent to 1.3% O2) (16).
In solid cancers, it is well established that uncontrolled 
proliferation leads to profound hypoxia, associated with tumor 
development, metabolic changes, metastatic propagation, 
immune response modulation, and increased mortality (17, 
18). Consequently, it could be assumed that intense blast cell 
proliferation would eventually decrease the oxygen availability 
by high consumption. This assumption is particularly difficult to 
validate by direct measurement in human BM. However, Fiegl 
et al. (19) demonstrated in total BM aspirates from AML patients 
that oxygen percentage was highly comparable to the normal 
counterpart. Using a rat model of an acute AML subtype, the 
promyelocytic leukemia, Jensen et al. (20) noted an increasing 
level of hypoxia during disease progression, comparable to that 
observed with solid tumours. In this model, both normal and 
leukemic cells stained with 2-nitroimidazole (hypoxic marker) 
underwent decreased proliferation. In agreement with this obser-
vation, the hypoxic culture of normal hematopoietic (21–23) and 
CML cells (24–27) led to decreased proliferation. Nevertheless, a 
small fraction of leukemic cells remained insensitive to hypoxia-
induced proliferation arrest (26), probably triggering tumor 
growth (20). Moreover, it has been established that mild hypoxia 
such as ≤3% O2 sustains both primary CML (24) and AML cell 
(28) maintenance longer than normoxia.
Low oxygen might also affect hematopoietic cells through the 
modulation of the stromal cells. Indeed, hypoxia has been shown 
to impact on survival, proliferation capability, and differentiation 
as well as metabolism of mesenchymal stem/stromal cells (MSCs) 
(29–31). Hypoxia triggers secretion by MSCs of numerous fac-
tors, including SDF-1, VEGF, and IL-6, known to promote HSC 
maintenance. Interestingly, even in normoxia, HSCs present a 
hypoxic profile when seeded on MSCs, suggesting appearance of 
“microhypoxic” regions (32, 33). Moreover, MSCs and hypoxic 
culture synergize to sustain in vitro normal stem cells (23) and 
primary AML cells (28). Finally, the poorly oxygenized niche 
enhances resistance to treatments (28, 34, 35), thus protecting 
from various stresses, such as DNA damage, cell death stimuli, or 
oxidative stress signals (36–38).
HYPOXiA-inDUCiBLe FACTORS in 
LeUKeMiAS
The master regulators mediating cell responses to hypoxia are the 
hypoxia-inducible factors (HIFs). These heterodimer complexes 
are composed of one of three oxygen-regulated HIF-alpha 
subunits (HIF-1alpha, HIF-2alpha, and HIF-3alpha) and the con-
stitutively expressed HIF-beta subunit [HIF-1-beta, also known 
as aryl hydrocarbon receptor nuclear translocator (ARNT)] 
(39–41). The HIF1A gene is ubiquitously expressed (42). HIF2A, 
also termed endothelial Per-ARNT-Sim (PAS) protein 1 (EPAS1), 
is expressed in a more tissue specific manner, particularly in blood 
vessels (39, 40, 43). Little is currently known about expression 
and function of HIF3A, but at least 10 splice variants have been 
described to date (44, 45). HIF-1alpha and HIF-2alpha proteins 
share similar structural domains such as an N-terminal basic 
helix-loop-helix (bHLH) domain involved in DNA binding, the 
two PAS domains allowing dimerization, an oxygen-dependent 
degradation domain (ODDD) plus N- and C-terminal transacti-
vation domains (NTAD and CTAD). Although HIF-3alpha also 
exhibits high similarity in bHLH and PAS domains, the lack of 
the CTAD precludes binding to p300 coactivator (45, 46). Under 
atmospheric conditions, HIF-alpha subunits are differentially 
hydroxylated by prolyl hydroxylase domain 1–3 (PHDs) on two 
proline residues in the ODDD, with oxygen and α-ketoglutarate 
as substrates. The hydroxylated motif allows binding to von 
Hippel–Lindau (VHL) tumor suppressor, which leads to HIF-
alpha ubiquitination and consequent degradation by 26S protea-
some (39–41, 47). In parallel, the hydroxylation of HIF-1alpha by 
factor inhibiting HIF-1 (FIH1) triggers inhibition of p300/CBP 
coactivator recruitment (48). PHD activity falls with decreasing 
oxygen levels, thereby triggering HIF-alpha stabilization and 
nuclear translocation where it heterodimerizes with HIF-1beta. 
HIF complexes bind to specific HIF-response elements consist-
ing of specific RCGTG sequences within target gene promoters. 
Although HIF-1 and HIF-2 share common targets, additional 
genomic regions and cofactor-binding specifically drive the tran-
scriptional initiation of genes involved in many pathways, such as 
angiogenesis, differentiation, stem cells maintenance, apoptosis, 
and invasion (35, 39, 40).
HIF-1alpha mainly participates in the initial response to acute 
hypoxia, whereas HIF-2alpha responds to chronic exposure 
(47, 49). Additionally, even in prolonged hypoxia HIF-1alpha 
undergoes feedback control, whereas HIF-2alpha is stabilized. 
The multiple HIF-3alpha splice variants appear essentially to 
regulate HIF-1alpha and HIF-2alpha activity by sequestrating 
HIF-1beta or by acting as dominant negative regulators (40, 44, 
45, 50). HIFs, moreover, can be regulated by oxygen-independent 
mechanisms. Factors involved in hematopoiesis such as MEIS1 
(51), TPO (52), and SCF (53, 54) positively regulate expression 
of HIFs. Conversely, factors implicated in metabolic changes like 
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the SIRT1 (55, 56) or SDH (57) inhibit the expression of HIFs. 
Furthermore, downregulation of HIFs may be achieved by tumor 
suppressor genes like p53 (58, 59) or GSK3 (60) and the upregula-
tion by oncogenes such as PI3K/AKT (60, 61) or mTORC1 (62). 
Genetic abnormalities encountered in leukemia such as the IDH 
mutation decrease expression of HIFs by stimulating PHD activ-
ity (63) or conversely, FLT3-ITD stimulates translation of HIFs 
via the PI3K/AKT pathway (40).
Elevated expression of HIFs is considered to be a marker 
of poor prognosis in solid cancers (64–77). Overall, increased 
expression of HIFs is correlated with tumor growth and resist-
ance to therapies, which leads to disease relapse (37). The subject 
is somewhat more complex and controversial in leukemia. 
Overexpression of HIF-1alpha in leukemia has been suggested 
as a marker of poor prognosis and chemotherapy outcomes 
(78–81). Elevated levels of HIF-1alpha are reported, in the major-
ity of studies, in AML (79, 82–84), acute promyelocytic leukemia 
(APL) (85), ALL (82), and CML (86, 87). Disease severity and 
survival have been shown to be influenced by HIF-1alpha levels, 
in AML and myelodysplastic syndromes (84, 88, 89); the protein 
expression of HIF-2alpha, usually absent in normal cells, has been 
observed in both AML and ALL, but has not been correlated with 
outcome (82, 90, 91). Thus, leukemic subtype, disease stage or the 
molecular abnormality involved might explain the variability. To 
explore potential functions of HIFs in leukemogenesis, various 
mouse models have been proposed (Table 1). Several studies have 
shown that inhibition of HIF-1alpha, either by RNAi targeting 
or by small molecular inhibition, resulted in a failure of primary 
cells to form in vitro colonies and decreased tumor growth and 
leukemic progression. In vivo, dramatic decrease and potential 
eradication of primary AML cell xenografts have been shown and 
a complete absence of leukemic induction in secondary trans-
plantation has been reported in cells in which HIF-1alpha was 
inhibited (79, 84, 85, 92). This has also been confirmed in ALL 
(93, 94) and CML (83, 87). Similarly, knockdown of HIF-2alpha 
with shRNA triggers leukemic inhibition (82, 85, 90), which is 
demonstrated in vitro by limited cellular proliferation as well as 
in vivo by absence or poor engraftment.
Hypoxia via HIFs may promote disease maintenance and 
progression through different mechanisms including energy 
metabolism (98–100), cycle and quiescence (101, 102), and 
immune function (103) that are important in normal physiology 
and deregulated in cancer (47, 104). On one hand, HIF-1alpha and 
HIF-2alpha influence signaling pathways relevant to leukemia 
maintenance and propagation. HIF-1alpha activates the Notch1 
pathway, which leads to leukemia invasion (94), and promotes 
the Wnt pathway, consequently preserving LSCs (93). On the 
other hand, HIF-1alpha acts as an inhibitor of the expression of 
tumor suppressor genes, such as p15, p16, p19, and p53 (79, 87). 
Indeed, HIF-1alpha-transactivated DNMT3a methylates DNA, 
which inhibits tumor suppressors and leads to tumor growth 
(79). In AML, DNMT3a plays a crucial role since more than 20% 
of patients exhibit DNMT3A mutation (105), conferring a global 
hypomethylation of DNA and predisposition to developing 
hematological diseases (106). In contrast, in T-ALL this mutation 
confers hypermethylation, so the contribution of hypomethyla-
tion and hypermethylation to disease development remains to be 
elucidated (106). Interestingly, taken from non-hematopoietic 
tissue and cancers, studies have explored the role of hypoxia in 
epigenetic modifications, through HIF-1alpha stabilization, such 
as DNA methylation, histone modifications, and non-coding 
RNA expression (107). Promoter methylation is modified by 
hypoxia and regulates neural progenitor cell fate (108). The his-
tone demethylase JMJD1A and 1B are targets of HIFs in normal 
and cancer cells (109–111). Finally in HIF-2alpha-deficient cells, 
transcriptomic approaches have identified deregulated genes 
involved in energetic and oxidative metabolisms, plus endoplas-
mic reticulum (ER) stress, indicating that HIF-2alpha protects 
AML cells from apoptosis induced by ER stress (90).
One consequences of the expression of HIFs is the promotion 
of quiescence, which favors chemoresistance. Hypoxia-induced 
HIF-1alpha promotes entry into G0/G1 and decreases S phase in 
AML cells through, in part, upregulation of p27 (112). Quiescence 
enhances chemoresistance of leukemic cells to cytosine arabino-
side (Ara-C) (112, 113) and adriamycin (ADR) (88), since these 
agents target cycling cells. Coculture of primary AML cells with 
stromal cells in hypoxia (3% O2) confers resistance to Ara-C 
through stabilization of HIFs and induction of quiescence (28). 
Antiapoptotic signaling is observed through increased XIAP 
level, an apoptosis-inhibitory protein, and the activation of the 
PI3K/AKT pro-survival pathway (112). HIF-1alpha activation 
by a PHD inhibitor, cobalt chloride (CoCl2), protects HL-60 
leukemic cells against arsenic trioxide (ATO) by inhibiting BAX 
and Caspase 3 and 9 and promoting HSP70 protein and p38/ERK 
pro-survival factors (114). In T-ALL, through Notch1 activation, 
HIF-1alpha induces BCL2 and BCL-XL upregulation and the 
downregulation of Caspase 3 and 9 activities, which decreased 
dexamethasone-induced apoptosis in leukemic cells (94).
Conversely, low oxygen and hypoxia-mimicking agents such 
as CoCl2 or desferrioxamine induce AML cell differentiation 
through HIF-1alpha accumulation (115, 116). In fact, HIF-1alpha 
mediates differentiation by binding to C/EBPα and promoting its 
transcriptional activity (115–117) as well as that of RUNX1 and 
PU.1 (118, 119). Additionally, C/EBPα/HIF-1alpha induces AML 
differentiation through c-MYC inhibition and further suppres-
sion of miR17 and miR20a expression. The knockdown of p21 
and STAT3, two inhibitory targets of miR17 and miR20A, reverses 
HIF-1alpha-induced AML differentiation (120). In renal cell 
carcinoma, HIF-1alpha inhibits c-MYC/MAX association, which 
decreases c-MYC promoter binding and thus blocks cells in G1 
(121). Conversely, HIF-2alpha triggers cell cycle progression and 
proliferation by enhancing the formation of c-MYC/MAX and its 
activity. Since HIF-2alpha and HIF-1alpha have dual effects on cell 
cycle progression according to cell types, more investigations are 
needed on their antagonistic effects in leukemias. Nguyen-Khac 
et al. (122) discovered a translocation involving TEL and ARNT 
in an AML patient exerting a dominant/negative activity on HIF-
1alpha. The fusion protein blocks leukemic differentiation, thus 
conferring a tumor suppressor function for HIF-1alpha. In line 
with this, data have previously shown that intermittent hypoxia 
slows down leukemic development in mice (123). However, 
in vivo hypoxia may have unrelated consequences on leukemic 
cell physiology. More recently, Velasco-Hernandez et  al. (124) 
using different AML models found reduced survival of mice 
TABLe 1 | Models used to characterize HIF1A and HIF2A as oncogenes in leukemias.
Leukemia Cell types Mouse models HiFs inhibition or overexpression Phenotypes Reference
CML Human cells
K562 Nude (in subcutaneous) Human HIF1A cDNA + l-ascorbic 
acida
No decreased tumor growth (83)
Mouse cells
Vav-Cre-HIF1aflox/flox 
transduced with  
BCR–ABL retrovirus
C57BL/6 J Vav-Cre-Hif1aflox/flox system No leukemia induction in second 
transplantation
Decreased LSCs number
(87)
AML Human cells
Primary NOD-SCID Echinomycinb Decreased/eliminated leukemia cells (84)
No leukemia induction in serial transplantation
Primary NOD-SCID gamma shHIF2A Decreased/no engraftment (90)
HL-60 NOD-SCID gamma shHIF2A Increased mice survival (82)
NB4 NOD-SCID gamma shHIF1A, shHIF2A, or EZN-2968c Increased mice survival (85)
Delayed leukemia progression
SKNO-1 Athymic nude Echinomycinb Decreased tumor growth (79)
HL-60 Nude (in subcutaneous) l-ascorbic acida Decreased tumor growth (83)
Mouse cells
PML-RARα Lin− 129Sv Ex vivo electroporation with 
EZN-2968c
Increased mice survival (85)
PML-RARα Lin− 129Sv EZN-2208c Increased mice survival (95)
ATRAd + EZN-2208c Synergy of both treatments to leukemia 
eradication
No leukemia induction in serial transplantation
FDCP1 DBA/2 Human HIF2A cDNA Accelerated leukemia progression (82)
Relapsed MllPTD/WT:Flt3ITD/WT C57BL/6 Ly5.1 Echinomycinb Decreased AML blasts (≤20%) (92)
Increased mice survival
A/E9a transgenic mouse 
cells
C57BL/6 J Human HIF1A cDNA Enhanced leukemia disease (79)
siHIF1A Suppressed leukemia disease
ALL Human cells
Jurkat Transwell matrigel-
coated chambers
Hypoxia (2% O2) Increased tumor invasion (94)
Sup-T1
Primary T-ALL NOD-SCID gamma shHIF1A Increased mice survival (93)
Decreased LSCs frequency
Mouse cells
Primary (NOTCH1-ΔE/
NGFR retrovirus)
NOD-SCID gamma Hif1aloxP/loxP/CreERT2/GFP system Increased mice survival (93)
al-ascorbic acid indirectly inhibits HIF-1alpha expression by inhibiting NF-κB translocation into the nucleus (83).
bEchinomycin binds the core-binding site of HIF-1alpha and inhibits its DNA-binding activity (96).
cEZN-2968 and EZN-2208 specifically target HIF-1alpha (85, 95, 97).
dATRA target RARα moiety in PML-RARα mutation of APL (95).
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transplanted with HIF-1alpha KO cells (Table 2). These observa-
tions were confirmed in myeloproliferative neoplasia through a 
FLT3ITD-induced mouse model (125). Overall, Hifa KO enhanced 
disease progression and severity, making it a tumor suppressor 
gene. However, authors show that HIF-1alpha deletion may 
promote compensatory effects via overexpression of HIF-2alpha, 
which may eventually mask the role of HIF-1alpha. This elevation 
was already seen in HIF-1alpha-deficient cells (90). The Hif2a KO 
in MLL-AF9-driven and Meis1/HoxA9-induced murine AML 
enhances LSCs development but, once leukemias are established, 
HIF-2alpha has no impact on their maintenance and propagation. 
Furthermore, double inhibition of HIF-1alpha and HIF-2alpha 
demonstrated that HIFs synergize to inhibit AML development, 
without any role in leukemic propagation (126). Transcriptomic 
analysis reveals that HIF-1alpha and HIF-2alpha promote a set 
of genes that fosters survival and proliferation of leukemic cells.
Off-target effects of shRNAs and poor specificity of drugs that 
inhibit HIFs compared to KO might explain this controversy 
between studies. However, KO may also induce slow cellular 
adaptation with compensatory effects. Differences may also arise 
from the model used, mouse versus human, and the different 
protumoral gene constructions used to generate the leukemia. It 
will be pertinent to assess the overexpression of HIFs in AML 
models, and thus observe whether increased HIF delays disease 
TABLe 2 | Models used to characterize HIF1A and HIF2A as tumor suppressor genes in leukemias.
Leukemia Cell types Mouse 
models
HiFs inhibition or overexpression Phenotypes Reference
CML Human
K562 – Mixture with 10% O2 for 5 or 22 + 1 or 
24 h of reoxygenation
Survival signals with 5 h hypoxia 
Death signals with 22 h hypoxia
(127)
AML Human
MLL-AF9 THP-1 transduced with 
HIF2A sgRNAs + Cas9 nuclease
– Two independent sgRNAs against the 
exon 12 of HIF2A
Same leukemic propagation than control (126)
Mouse
hMRP8-PML-RARα FVB-NICO Intermittent hypoxia equivalent to an 
altitude of 6000 m (≈10% O2) for 18 h/day
Increased mice survival 
Decreased tumor infiltration/invasion
Hif1afl/fl; Mx1-Cre transduced with  
A/E9a retrovirus
B6SJL Hif1afl/fl/CreERT2 system HIF-1alpha does not affect AML initiation/
progression
(123)
Decreased mice survival in second 
transplantation
Hif1afl/fl; Mx1-Cre transduced with 
HoxA9-Meis1 retrovirus
C57BL/6 
Ly5.1/
Ly5.2
Hif2afl/fl; Vav-iCre system HIF-1alpha does not affect AML initiation/
progression
(124)
Hif1afl/fl; Mx1-Cre transduced with 
MLL-AF9 retrovirus
HIF-1alpha does not affect AML initiation/
progression
Hif2afl/fl; Vav-iCre transduced with 
Meis1 and HoxA9 retroviruses
Decreased mice survival
Same AML aggressiveness to control mice
MLL-AF9KI/+; Hif2afl/fl; Vav-iCre C57BL/6 
Ly5.1/
Ly5.2
Hif1afl/fl; Hif2afl/fl; Vav-iCre system Accelerated leukemia disease (126)
Hif1afl/fl; Hif2afl/fl; Vav-iCre transduced 
with Meis1 and HoxA9 retrovirus
Decreased mice survival
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development and, even, eradicate leukemia. HIFs may also dif-
ferently impact on LSCs and more mature blasts cells, conferring 
pro-survival effect on LSCs and differentiation on blasts. In favor 
of this hypothesis, intermittent hypoxia increases survival of APL 
mice (123). Similarly, in CML, HIF-1alpha induction following 
short (5 h) hypoxia exposure delivered a survival signal to cells, 
whereas it promoted cell death within a longer period (22  h) 
(127). In the ALL model, 24  h-exposure to hypoxia conferred 
chemoresistance in contrast to longer exposure (48–72 h) (128). 
These data suggest that duration of hypoxia incubation may 
promote or inhibit leukemia progression and maintenance, thus 
explaining the oncogenic or tumor suppressor activity. The link 
between HIFs and tumor suppressor activity has been previously 
demonstrated in other cancers (71, 129–131). Taken together, 
these data suggest that not only the level but also the duration 
of activity dictates HIF action and hence cellular response in 
leukemia.
THeRAPeUTiC STRATeGieS: TARGeTinG 
HiFs OR nOT?
In light of the results summarized above, it could be difficult 
to affirm that downregulation of HIFs could be a therapeutic 
approach. Nevertheless, chemical inhibitors have been tested 
and the proof-of-concept was first illustrated using echinomycin, 
which blocks HIF-1alpha-binding activity. This drug preferen-
tially targets AML LSCs through apoptosis, decreasing leukemia 
burden, prolonging mouse survival, and abrogating disease 
development in secondary transplantation (84, 92). Echinomycin 
does not impact on self-renewal and differentiation of normal 
HSCs, which makes it an ideal molecule to treat leukemia (92). 
l-ascorbic acid has also been shown to inhibit expression of HIF-
1alpha in CML cells and consequently reduces tumor growth. 
This effect is specific to HIF-1alpha since its overexpression in 
l-ascorbic acid-treated mice antagonizes leukemic growth inhibi-
tion (83). In APL, EZN-2968 and EZN-2208 confer antileukemic 
activity and prolong mouse survival; in combination with all-
trans retinoic acid (ATRA), leukemia eradication was observed, 
along with survival of mice; fortunately, both compounds are 
non-toxic to normal HSCs (85, 95). Overall, these data offer new 
therapeutic options, targeting HIF in leukemia with no impact on 
normal hematopoiesis. Another approach will be the combina-
tion of HIF inhibitors with treatments capable of determining the 
departure of LSCs from quiescence, and then with treatments that 
target cycling cells, such as Ara-C.
An alternative strategy will consist of taking advantage 
of hypoxia to activate drugs and thus to target LSCs in the 
niche. TH-302 is a hypoxia-activated prodrug, which exhib-
its a specific cytotoxicity in hypoxia (132, 133). In primary 
AML, TH-302 hampers tumor growth through multiple 
mechanisms (cycle arrest, DNA cross-linking, DNA damage). 
In mouse models, it decreases leukemia burden and prolongs 
survival (133). PR-104 quickly undergoes alcohol hydrolysis 
and induces DNA cross-linking in hypoxic cells, impairs ALL 
progression, decreases tissue infiltration, and prolongs mice 
survival (134, 135). In a phase I/II study, PR-104 reduced 
the number of AML and ALL cells in refractory and relapsed 
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patients (136). Despite some side effects, including myelosup-
pression, febrile neutropenia, and infections, collectively, 
these results propose innovative therapies for leukemia based 
on hypoxia-activated prodrugs.
COnCLUSiOn
Overall, these data argue that hypoxia and HIF-mediated signal-
ing play a crucial role in leukemia and leukemogenic processes. 
However, they conflict in determining whether HIFs act as 
oncogenes or tumor suppressors, certainly because of the dif-
ferent leukemic models, study design, oxygen level, and hypoxia 
duration. However, therapies targeting hypoxia and HIFs have 
proven their efficacy in treating mouse models and may benefit 
leukemic patients.
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